Bharat Biotech has finished the Phase 2/3 trials of the Covaxin for kids under 18 years of age and will submit the data by next week to the DCGI, said Krishna Ella, Chairman and Managing Director of Bharat Biotech. He said the production of Covaxin will reach 55 million doses in October.

“We are supplying 35 million covid-19 vaccines this month. Next month we will for sure supply 55 million doses,” he said. Krishna also said if the government permits, the company will export the doses, though we are not in a hurry to see overseas markets.

India will resume the export of Covid-19 vaccines in the 4th quarter of 2021 under the Vaccine Maitri Programme and achieve its commitment to the COVAX global pool. Still, vaccinating its residents remains the top-most priority of the administration, Union Health Minister Mansukh Mandaviya said.